A rumor regarding Crispr Therapeutics (CRSP) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of Crispr are down 1% to $52.70 in morning trading.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $74 from $82 at Chardan
- Cathie Wood Doubles Down on This AI Stock, Cuts GitLab (GTLB) Again
- Crispr Therapeutics AG Faces Stock Price Slide
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- Citizens JMP healthcare analysts hold an analyst/industry conference